Hartmut Beck

Drug Discovery Laboratory (Norway) — Norway

Medicine · Health Sciences

11h-index748citations36works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(5), Computational Drug Discovery Methods(5), Cancer, Hypoxia, and Metabolism(5), interferon and immune responses(5), Asymmetric Synthesis and Catalysis(4)

Publications36 total

CACHE Challenge #1: Targeting the WDR Domain of LRRK2, A Parkinson’s Disease Associated Protein
UNC Libraries·2025Open Access
CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2
2025Open Access
CACHE Challenge #2: Targeting the RNA Site of the SARS-CoV-2 Helicase Nsp13
Journal of Chemical Information and Modeling·2025· 8 citedOpen Access
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy
Journal of Medicinal Chemistry·2025Open Access
Abstract 6978: Discovery and characterization of BAY-805, a potent and selective DUB inhibitor of ubiquitin specific peptidase USP21
Cancer Research·2025
CACHE Challenge #2: Targeting the RNA Site of the SARS-CoV-2 Helicase Nsp13
2025Open Access
CACHE Challenge #2: Targeting the RNA Site of the SARS-CoV-2 Helicase Nsp13
2025· 2 citedOpen Access
CACHE Challenge #2: Targeting the RNA Site of the SARS-CoV-2 Helicase Nsp13
2025· 1 citedOpen Access
Toward target 2035: EUbOPEN - a public–private partnership to enable & unlock biology in the open
UNC Libraries·2024Open Access
Toward target 2035: EUbOPEN - a public–private partnership to enable & unlock biology in the open
RSC Medicinal Chemistry·2024· 3 citedOpen Access
CACHE Challenge #1: Targeting the WDR Domain of LRRK2, A Parkinson’s Disease Associated Protein
Journal of Chemical Information and Modeling·2024· 23 citedOpen Access
CACHE Challenge #1: targeting the WDR domain of LRRK2, a Parkinson’s Disease associated protein
2024· 5 citedOpen Access
Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21
Journal of Medicinal Chemistry·2023· 24 citedOpen Access
Target 2035 – an update on private sector contributions
RSC Medicinal Chemistry·2023· 17 citedOpen Access
Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory
Drug Discovery Today·2022· 169 citedOpen Access
Target 2035 – update on the quest for a probe for every protein
RSC Medicinal Chemistry·2021· 77 citedOpen Access
CCDC 1906048: Experimental Crystal Structure Determination
The Cambridge Structural Database·2020Open Access
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Journal of Medicinal Chemistry·2020· 31 citedOpen Access
Front Cover: Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia (ChemMedChem 10/2018)
ChemMedChem·2018Open Access
Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia
ChemMedChem·2018· 74 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Kristina Edfeldt(12), A.M. Edwards(12), Alexander Hillisch(11), Peter J. Brown(10), C.H. Arrowsmith(9), Uta Lessel(9), Suzanne Ackloo(8), Albina Bolotokova(8), Irene Chau(8), Katrin Denzinger(8), Elisa Gibson(8), Rachel Harding(8), Laurent Hoffer(8), Anders Hogner(8), John J. Irwin(8), Jan H. Jensen(8), Sijie Liu(8), Jens Meiler(8), Rocco Moretti(8), Amit Pandit(8)